Latest Balance Sheet News

Opthea has significantly reduced its operating costs and settled a key financial liability, positioning itself for a strategic review aimed at unlocking shareholder value.

GWA reported modest revenue and earnings growth in FY25, driven by strong performance in Australia and the UK despite a tough New Zealand market. The company also initiated a $30 million on-market share buyback and increased its fully franked dividend.

Jade Gas Holdings has achieved continuous gas flow from two production wells and secured its first LNG sales agreement with Mongolia’s largest natural gas importer, UB Metan LLC. The company also raised $5 million to support its commercial operations.

Elevate Uranium has raised $25 million through a well-supported placement, boosting its cash reserves to nearly $44 million. The funds will accelerate its proprietary U-pgrade™ pilot plant and expand uranium resource drilling in Namibia and Australia.

Po Valley Energy reported consistent gas production and strong cash flow in Q3 2025, while advancing development plans and a new gas sales agreement in Italy.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug candidate NUZ-001 and strengthened its balance sheet with a $5.2 million capital raise. The company is now poised to enter the pivotal HEALEY ALS Platform Trial, marking a significant step forward in its neurodegenerative disease program.

archTIS has significantly expanded its U.S. footprint through the acquisition of Spirion LLC and a new Department of Defense contract, supported by a A$20.5 million capital raise. These moves position the company for accelerated growth in the lucrative U.S. defense and enterprise cybersecurity markets.

NGX Limited progresses its Malingunde graphite project with key technical studies and downstream qualification, while advancing uranium exploration in Namibia. Market dynamics and regulatory shifts position NGX favorably in the clean energy minerals sector.

Omni Bridgeway reported a strong start to FY26 with A$136.6 million in cash investment proceeds and a robust pipeline of nearly A$318 million in potential new commitments. The company also settled a long-standing legal liability and is progressing well with fund capital raising.

NewPeak Metals has completed acquisition of 100% ownership of the Las Opeñas exploration permits in Argentina, with drilling scheduled for early 2026. The company also advances drilling preparations at its Tansey Gold Project in Australia, supported by strong insider buying.

Aspire Mining Limited reports significant progress on its Ovoot Coking Coal Project, securing exclusive marketing rights and aligning infrastructure development with government-backed transport projects.

Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.